Sec Form 13D Filing - Frazier Life Sciences IX, L.P. filing for - 2025-08-20

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Aggregate Amount represents (i) 3,566,912 shares of Common Stock held directly by Frazier Life Sciences IX, L.P., and (ii) 163,643 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The Aggregate Amount represents (i) 5,703 shares of Common Stock held directly by the Reporting Person, (ii) 76,779 shares of Common Stock that are issuable upon the exercise of options held directly by the Reporting Person, (iii) 3,566,912 shares of Common Stock held directly by Frazier Life Sciences IX, L.P., and (iv) 163,643 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The Percent of Class is calculated based on (i) 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025 and (ii) 76,779 shares of Common Stock that are issuable upon the exercise of options held directly by the Reporting Person.


SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D





SCHEDULE 13D

 
Frazier Life Sciences IX, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, C FO of FHMLS IX, L.L.C., GP of FHMLS IX, L.P., GP of Frazier Life Sciences IX, L.P.
Date:08/20/2025
 
FHMLS IX, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS IX, L.L.C., GP of FHMLS IX, L.P.
Date:08/20/2025
 
FHMLS IX, L.L.C.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS IX, L.L.C.
Date:08/20/2025
 
Frazier Life Sciences X, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:08/20/2025
 
FHMLS X, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:08/20/2025
 
FHMLS X, L.L.C.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date:08/20/2025
 
Frazier Life Sciences Public Fund, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:08/20/2025
 
FHMLSP, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:08/20/2025
 
FHMLSP, L.L.C.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:08/20/2025
 
Frazier Life Sciences Public Overage Fund, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
Date:08/20/2025
 
FHMLSP Overage, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
Date:08/20/2025
 
FHMLSP Overage, L.L.C.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Date:08/20/2025
 
Frazier Life Sciences XI, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:08/20/2025
 
FHMLS XI, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:08/20/2025
 
FHMLS XI, L.L.C.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:08/20/2025
 
James N. Topper
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:08/20/2025
 
Patrick J. Heron
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:03/06/2025
 
Albert Cha
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:08/20/2025
 
James Brush
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:08/20/2025
 
Daniel Estes
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
Date:08/20/2025
primary_doc.xml